The role of molecular and genomic analysis in the diagnostic work-up of solid tumors continues to expand, with dramatic implications for clinicians, pathologists, and patients. With the recent surge of next-generation sequencing (NGS) adoption into clinical diagnostics laboratories, the possibilities for broad genomic surveillance have exploded over the past decade, with single-gene testing giving way to panels of dozens to hundreds of genes, with the prospect of routine exome or even whole genome sequencing looming on the horizon. With the increasing application of NGS for use in personalized cancer care, pathologists are more than ever required to actively participate as consultants on test selection and integrated clinical interpretation.
This course will provide an overview of current next generation technologies and their capabilities and indications for use in solid tumor diagnosis and management. The course will reinforce these concepts with examples of personalized genomic analysis and management of a variety of solid tumors. Finally, future trends in personalized tumor management will be covered, including possibilities for testing of emerging specimen types, including fine-needle aspirates and blood and other bodily fluids, from which trace cancer signals can be detected.
• Demonstrate familiarity with next-generation sequencing(NGS)
• Recognize the indications, specimen requirements, applications, limitations and implementation of NGS-based test for solid tumor testing
• Understand interpretive principles for review and reporting of clinically relevant findings within the proper solid tumor contexts
This course is funded by an independent education grant from Illumina.